Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'DEBRISOQUINE HYDROXYLATION PHENOTYPE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 36 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Yasui-Furukori, N; Kondo, T; Suzuki, A; Mihara, K; Tokinaga, N; Inoue, Y; Otani, K; Kaneko, S
      Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol

      SCHIZOPHRENIA RESEARCH
    2. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    3. Suzuki, Y; Someya, T; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

      THERAPEUTIC DRUG MONITORING
    4. Fang, J; Mckay, G; Song, JX; Remillrd, A; Li, XM; Midha, K
      In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    5. Fukuda, R
      Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    6. Shimoda, K; Morita, S; Yokono, A; Someya, T; Hirokane, G; Sunahara, N; Takahashi, S
      CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients

      THERAPEUTIC DRUG MONITORING
    7. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Ono, S; Kaneko, S; Otani, K; Inoue, Y
      Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      THERAPEUTIC DRUG MONITORING
    8. Otani, K; Aoshima, T
      Pharmacogenetics of classical and new antipsychotic drugs

      THERAPEUTIC DRUG MONITORING
    9. Someya, T; Suzuki, Y; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    10. Kondo, T; Suzuki, A; Mihara, K; Yasui, N; Kaneko, S
      CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese

      MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY
    11. Kudo, S; Ishizaki, T
      Pharmacokinetics of haloperidol - An update

      CLINICAL PHARMACOKINETICS
    12. Yasui, N; Kondo, T; Otani, K; Furukori, H; Mihara, K; Suzuki, A; Kaneko, S; Inoue, Y
      Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    13. Tanaka, E; Hisawa, S
      Clinically significant pharmacokinetic drug interactions with psychoactivedrugs: antidepressants and antipsychotics and the cytochrome P450 system

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    14. Naranjo, CA; Sproule, BA; Knoke, DM
      Metabolic interactions of central nervous system medications and selectiveserotonin reuptake inhibitors

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    15. Pan, LP; Vander Stichele, R; Rosseel, MT; Berlo, JA; De Schepper, N; Belpaire, FM
      Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients

      THERAPEUTIC DRUG MONITORING
    16. Pan, L; Belpaire, FM
      In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    17. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Otani, K; Kaneko, S; Inoue, Y
      Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    18. Furukori, H; Kondo, T; Yasui, N; Otani, K; Tokinaga, N; Nagashima, U; Kaneko, S; Inoue, Y
      Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

      PSYCHOPHARMACOLOGY
    19. PAN LP; DEVRIENDT C; BELPAIRE FM
      IN-VITRO CHARACTERIZATION OF THE CYTOCHROME-P450 ISOENZYMES INVOLVED IN THE BACK OXIDATION AND N-DEALKYLATION OF REDUCED HALOPERIDOL

      Pharmacogenetics
    20. Usuki, E; Van der Schyf, CJ; Castagnoli, N
      Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP

      DRUG METABOLISM REVIEWS
    21. YASUI N; OTANI K; KONDO T; SUZUKI A; FURUKORI H; KANEKO S; INOUE Y
      CORRELATION BETWEEN STEADY-STATE PLASMA-CONCENTRATIONS (CSS) OF BROMPERIDOL AND HALOPERIDOL

      Progress in neuro-psychopharmacology & biological psychiatry
    22. SUZUKI A; OTANI K; MIHARA K; YASUI N; KANEKO S; INOUE Y; HAYASHI K
      EFFECTS OF THE CYP2D6 GENOTYPE ON THE STEADY-STATE PLASMA-CONCENTRATIONS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN JAPANESE SCHIZOPHRENIC-PATIENTS

      Pharmacogenetics
    23. SPROULE BA; NARANJO CA; BREMNER KE; HASSAN PC
      SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND CNS DRUG-INTERACTIONS - ACRITICAL-REVIEW OF THE EVIDENCE

      Clinical pharmacokinetics
    24. LANE HY; LIN HN; HU OYP; CHEN CC; JANN MW; CHANG WH
      BLOOD-LEVELS OF REDUCED HALOPERIDOL VERSUS CLINICAL EFFICACY AND EXTRAPYRAMIDAL SIDE-EFFECTS OF HALOPERIDOL

      Progress in neuro-psychopharmacology & biological psychiatry
    25. LANE HY; CHANG WH; CHANG YC; HU OYP; LIN HN; JANN MW; HU WH
      DOSE-DEPENDENT REDUCED HALOPERIDOL HALOPERIDOL RATIOS - INFLUENCE OF PATIENT-RELATED VARIABLES

      Psychiatry research
    26. LANE HY; HU OYP; JANN MW; DENG HC; LIN HN; CHANG WH
      DEXTROMETHORPHAN PHENOTYPING AND HALOPERIDOL DISPOSITION IN SCHIZOPHRENIC-PATIENTS

      Psychiatry research
    27. HASSELSTROM J; YUE QY; SAWE J
      THE EFFECT OF CODEINE ON GASTROINTESTINAL TRANSIT IN EXTENSIVE AND POOR METABOLIZERS OF DEBRISOQUINE

      European Journal of Clinical Pharmacology
    28. SHEN WW
      THE METABOLISM OF PSYCHOACTIVE-DRUGS - A REVIEW OF ENZYMATIC BIOTRANSFORMATION AND INHIBITION

      Biological psychiatry
    29. GOLDBERG RJ
      THE P-450 SYSTEM - DEFINITION AND RELEVANCE TO THE USE OF ANTIDEPRESSANTS IN MEDICAL-PRACTICE

      Archives of family medicine
    30. CHANG WH; JANN MW; CHIANG TS; LIN HN; HU WH; CHIEN CP
      PLASMA HALOPERIDOL AND REDUCED HALOPERIDOL CONCENTRATIONS IN A GERIATRIC POPULATION

      Neuropsychobiology
    31. LINNET K; WIBORG O
      INFLUENCE OF CYP2D6 GENETIC-POLYMORPHISM ON RATIOS OF STEADY-STATE SERUM CONCENTRATION TO DOSE OF THE NEUROLEPTIC ZUCLOPENTHIXOL

      Therapeutic drug monitoring
    32. LANE HY; LIN HN; HWU HG; JANN M; HU WH; CHANG WH
      HALOPERIDOL PLASMA-CONCENTRATIONS IN TAIWANESE PSYCHIATRIC-PATIENTS

      Journal of the Formosan Medical Association
    33. MILTON GV; JANN MW
      EMERGENCY TREATMENT OF PSYCHOTIC SYMPTOMS - PHARMACOKINETIC CONSIDERATIONS FOR ANTIPSYCHOTIC-DRUGS

      Clinical pharmacokinetics
    34. LAM YWF; JANN MW; CHANG WH; YU HS; LIN SK; CHEN H; DAVIS CM
      INTRAETHNIC AND INTERETHNIC VARIABILITY IN REDUCED HALOPERIDOL TO HALOPERIDOL RATIOS

      Journal of clinical pharmacology
    35. SHEN WW
      CYTOCHROME-P450 MONOOXYGENASES AND INTERACTIONS OF PSYCHOTROPIC-DRUGS- A 5-YEAR UPDATE

      International journal of psychiatry in medicine
    36. BALANTGORGIA AE; BALANT LP; ANDREOLI A
      PHARMACOKINETIC OPTIMIZATION OF THE TREATMENT OF PSYCHOSIS

      Clinical pharmacokinetics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 10:13:12